Loading
QuidelOrtho Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 19 Feb 2026.
QuidelOrtho Corp: what insiders have been doing
QuidelOrtho Corp, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). The last twelve months, up to 18 October 2026, brought 37 filings signed by 14 insiders.
No insider sold shares on the market over the period. Instead, the filings list 8 purchases totalling €1.1M, made by 6 insiders. Unlike grants, an open-market purchase is paid for by the insider, at the market price. On the buying side, the filings list 4 senior executives, 1 finance chief and 1 chief executive among the declarants. At €433k, the purchase published on 20 November 2025 by Blaser Brian J. is the largest of the period.
The data flag 7 purchases as part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The clock since the last published purchase (13 February 2026) now reads 247 days. Typically, a trade is published a median of 3 days after it takes place. US insiders must file a Form 4 within two business days of a trade.
For context, the typical company on the same exchange (median of 5,812 companies) published 19 filings over the same period, against 37 filings here. Over the whole record (from 2022), the tally stands at 10 purchases and 25 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 28 December 2025 lists revenue at 2.73 bn USD and net income at -1.13 bn USD.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Cytosorbents Corp also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
217
Thresholds
n/a
Buy Volume
€1M
10 ops. · all time
Sell Volume
€301M
25 ops. · all time
Who traded when
BuySaleBrian J. Blaser3 buys
Joseph M. Busky3 buys
Ann D. Rhoads1 buy
Carlyle Group Inc.1 sale
Joseph D. Wilkins Jr.1 buy
Mary Lake Ph D. Polan1 buy
+1 other insider
Since the insiders bought
- -55.4%Entry US$23.13 · Close at T+90 US$10.32
- -55.4%Entry US$23.13 · Close at T+90 US$10.32
- -55.4%Entry US$23.13 · Close at T+90 US$10.32
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 22,632 of 24,161 companies
17.9
score / 100
Value10
Quality26
FCF yld-9.4%
Earn yld-128%
EV/EBITDA·
ROE-46%
Gross mgn47%
Net mgn-41%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$13.87
Analyst consensus
3 analysts2.67/5
US$12.00Target US$14.67(+6%)US$20.00
Income statement
RevenueUS$2.7B
Gross profitUS$1.3B47% margin
EBITDA-US$482.6M-18% margin
Net income-US$1.1B-39.2% margin
Valuation
PER (forward)9.7x
P/Book0.5x
Beta0.78
Balance sheet & cash
Market capUS$951.1M
Total debtUS$2.8B
Free Cash Flow-US$83M
Debt / Equity173%
Profitability & ownership
ROE-45.9%
ROA0.4%
% insiders0.9%
% institutions124.2%
Last declaration on 17 September 2026
Declarations217 total
2,566 shares0Common StockSEC:0002036238-26-000005:0
921 shares@ US$10.630.0014% mcap100.0% of flowCommon StockSEC:0002036238-26-000005:1
446 shares0Common StockSEC:0002123618-26-000011:0
162 shares@ US$14.300.0003% mcap10.0% of flowCommon StockSEC:0002123618-26-000011:1
1,659 shares0Common StockSEC:0001238916-26-000004:0
497 shares0Common StockSEC:0001238916-26-000004:1
6,829 shares0Common StockSEC:0001238916-26-000002:0
6,829 shares0Common StockSEC:0001482197-26-000002:0
1,946 shares0Common StockSEC:0002045799-26-000008:0
528 shares@ US$11.590.0005% mcap26.0% of flowCommon StockSEC:0002123618-26-000007:1
699 shares@ US$11.590.0006% mcap63.7% of flowCommon StockSEC:0002045799-26-000008:1
1,459 shares0Common StockSEC:0002123618-26-000007:0
3,508 shares0Common StockSEC:0002123618-26-000005:0
1,269 shares@ US$11.900.0012% mcap64.1% of flowCommon StockSEC:0002123618-26-000005:1
3,238 shares0Common StockSEC:0002045799-26-000006:0
4,925 shares0Common StockSEC:0001385091-26-000012:0
1,519 shares@ US$14.780.0022% mcap10.0% of flowCommon StockSEC:0001385091-26-000012:1
3,370 shares@ US$23.662334.5% of flowCommon StockSEC:0001385091-26-000008:0
Canonical exit: 14 May 2026 (T+90)
10,000 shares@ US$23.9586100.0% of flowCommon StockSEC:0001377832-26-000003:0
Canonical exit: 14 May 2026 (T+90)
10,540 shares@ US$23.592123.8% of flowCommon StockSEC:0001492289-26-000006:0
Canonical exit: 14 May 2026 (T+90)
5,968 shares0Common StockSEC:0001385091-26-000006:0
3,198 shares0Common StockSEC:0001833942-26-000006:0
1,127 shares0Common StockSEC:0002045799-26-000004:0
1,610 shares0Common StockSEC:0001833942-26-000004:0
2,938 shares0Common StockSEC:0002036238-26-000002:0
25 of 217 declarations
About QuidelOrtho Corp
QuidelOrtho Corp. is a U.S.-based in vitro diagnostics company listed on Nasdaq under the ticker QDEL in the United States. The company is positioned as a global diagnostics specialist serving hospitals, clinical laboratories, transfusion medicine workflows, and point-of-care testing environments. Its business model centers on delivering fast, reliable, and increasingly automated diagnostic results across the care continuum. The portfolio spans clinical chemistry, immunoassay, immunohematology, molecular diagnostics, and rapid point-of-care testing, supported by reagents, consumables, software, and related services. ([quidelortho.com](https://www.quidelortho.com/us/en?utm_source=openai))
The current company was created through the merger of Quidel Corporation and Ortho Clinical Diagnostics, which closed on May 27, 2022. Quidel contributed a long legacy in rapid and decentralized testing, while Ortho brought scale in high-complexity laboratories and transfusion medicine. QuidelOrtho is headquartered in San Diego, California, at 9975 Summers Ridge Road. The company traces its innovation heritage back to 1979 through Quidel’s origins and highlights a combined history built on decades of diagnostic expertise. ([ir.quidelortho.com](https://ir.quidelortho.com/news/news-release-details/2022/QuidelOrtho-Formed-by-the-Completion-of-Transaction-Combining-Quidel-and-Ortho-Clinical-Diagnostics/default.aspx?utm_source=openai))
Read moreShow less
Operationally, QuidelOrtho’s core business lines include VITROS systems for clinical chemistry and immunoassay testing, SOFIA and QUICKVUE products for point-of-care use, ORTHO solutions for immunohematology and blood banking, and SOLANA and LYRA molecular platforms. The company also sells broad assay menus, laboratory software, and supporting consumables. QuidelOrtho states that it offers roughly 550 assays and serves more than 140 countries and territories, underscoring a sizable international footprint. ([quidelortho.com](https://www.quidelortho.com/us/en?utm_source=openai))
In competitive terms, QuidelOrtho is one of the larger pure-play in vitro diagnostics companies, with a diversified mix of centralized lab testing, transfusion medicine, and near-patient testing. Its competitive edge comes from breadth of menu, installed base, platform integration, and the ability to support customers across the full healthcare pathway, from hospitals and reference labs to clinics and retail-adjacent testing. Management has also emphasized that the business has been transitioning away from COVID-driven volatility toward a more durable and diversified diagnostics profile. ([ir.quidelortho.com](https://ir.quidelortho.com/news/news-release-details/2022/QuidelOrtho-Formed-by-the-Completion-of-Transaction-Combining-Quidel-and-Ortho-Clinical-Diagnostics/default.aspx?utm_source=openai))
Recent developments are important for investors. In February 2026, QuidelOrtho reported fourth-quarter and full-year 2025 results, citing growth in Labs and TRIAGE and further adjusted EBITDA margin expansion. In April 2026, it released preliminary first-quarter 2026 revenue and updated full-year guidance, reflecting a softer respiratory season and China-specific headwinds. The company also announced the acquisition of LEX Diagnostics in spring 2026, which adds an ultra-fast molecular platform for point-of-care testing and supports its strategic push into faster molecular diagnostics. For French-, Belgian- and Swiss-based investors, QDEL is therefore best viewed as a healthcare diagnostics name with exposure to hospital volumes, respiratory testing cycles, China demand, and execution on its industrial and M&A strategy. ([quidelortho.com](https://www.quidelortho.com/us/en/resources/press-releases/quidelortho-reports-fourth-quarter-and-full-year-2025-financial-results?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
